...
首页> 外文期刊>Vaccine >Development of a porcine reproductive and respiratory syndrome virus differentiable (DIVA) strain through deletion of specific immunodominant epitopes.
【24h】

Development of a porcine reproductive and respiratory syndrome virus differentiable (DIVA) strain through deletion of specific immunodominant epitopes.

机译:通过缺失特定的免疫显性表位开发猪繁殖与呼吸综合征病毒可分化株(DIVA)。

获取原文
获取原文并翻译 | 示例
           

摘要

The availability of a DIVA (differentiating infected from vaccinated animals) vaccine is very important for the control and eradication of endemic infectious diseases such as porcine reproductive and respiratory syndrome (PRRS). Previous studies in our laboratory identified several B-cell linear epitopes consistently recognized by convalescent sera obtained from pigs infected with a North American porcine reproductive and respiratory syndrome virus (PRRSV) strain. To ascertain if one or more of these immunodominant epitopes can be used as the basis of DIVA differentiation, we selected two epitope markers previously identified on the non-structural protein 2 (PRRSV NSP2, predictably the viral protein most likely to tolerate large deletions). The choice of these epitopes was primarily based on their immunodominance and their deletion were performed along the backbone of the wild-type cDNA infectious clone (FL12). We were able to successfully rescue a mutant that fulfilled the requirements for a DIVA marker strain, such as: efficient growth of the deletion mutant in vitro and in vivo and induction of specific seroconversion as measured by a commercial ELISA kit, with absence of a marker-specific peptide-ELISA response in 100% (n=15) of the inoculated animals. In summary, our results provide proof of concept that DIVA PRRSV vaccines can potentially be developed by deletion of individual "marker" immunodominant epitopes.
机译:DIVA(与疫苗接种的动物进行区别感染)疫苗的可用性对于控制和根除地方性传染病(如猪的生殖和呼吸系统综合症(PRRS))非常重要。我们实验室中的先前研究确定了从感染了北美猪繁殖与呼吸综合征病毒(PRRSV)株的猪中恢复的血清中一致识别的几种B细胞线性表位。为了确定这些免疫优势表位中的一个或多个是否可以用作DIVA分化的基础,我们选择了先前在非结构蛋白2(PRRSV NSP2,可预测为最有可能耐受大缺失的病毒蛋白)上鉴定的两个表位标记。这些表位的选择主要是基于其免疫优势,其删除是沿着野生型cDNA感染性克隆(FL12)的骨架进行的。我们能够成功拯救出满足DIVA标记菌株要求的突变体,例如:缺失突变体在体外和体内的有效生长,以及通过商业ELISA试剂盒测量的诱导特异性血清转化,而没有标记100%(n = 15)的被感染动物体内的特异性免疫反应。总而言之,我们的结果提供了概念验证,即DIVA PRRSV疫苗可以通过删除单个“标记”免疫优势表位来开发。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号